Pulmonary cytolytic thrombi (PCT) is an uncommon complication after hematopoietic cell transplantation. Although the pathogenesis is unknown, patients typically respond to systemic corticosteroid treatment. Considering corticosteroids may impair GVL reactions, we reviewed the records of 324 pediatric patients who received a transplant for leukemia and compared the outcomes of those with PCT (n ¼ 14) to those without PCT (n ¼ 310). PCT patients had a significantly more acute GVHD (aGVHD) and chronic GVHD (cGVHD). Though 3-year non-relapse mortality and OS were similar, there was significantly less relapse in patients with PCT compared to those without PCT (0 vs 28%, P ¼ 0.02), regardless of the presence or absence of aGVHD. In multivariate analysis, grade II-IV aGVHD (P ¼ 0.02), cGVHD (P ¼ 0.01) and development of PCT (Po0.01) were independently associated with less relapse. These data suggest that patients with PCT are at greater risk for GVHD, but at lower risk of leukemia relapse.
Introduction
Both infectious and noninfectious lung complications occur frequently after allogeneic hematopoietic cell transplantation (allo-HCT). Pulmonary cytolytic thrombi (PCT) is a rare post transplant lung complication that we have previously described. [1] [2] [3] PCT is more commonly reported in children, typically presenting with low-grade fevers, cough and respiratory distress. Chest computed tomography findings range from small, peripheral nodules to large, diffuse infiltrates [1] [2] [3] [4] ( Figure 1a ). Because the signs and symptoms of PCT mimic other post transplant pulmonary complications, including bronchiolitis obliterans with organizing pneumonia and infection (bacterial, fungal or viral), tissue biopsy is required for diagnosis. The pathologic appearance of PCT is unique and bears no resemblance to other infectious and noninfectious post transplant lung complications. Microscopically, PCT is characterized by occlusive vascular lesions in distal pulmonary vessels with entrapped leukocytes and amorphous material. There is associated endothelial disruption and infarction of adjacent lung tissue 1 ( Figure 1b) . In samples where viable cells can be identified, immunohistochemistry shows mainly donor-derived macrophages. 3 Blood, bronchoalveolar fluid and lung biopsy are negative for infectious organisms. 1 Though the pathogenesis of PCT is not currently known, endothelial injury secondary to GVHD, infections, chemotherapy and radiation therapy have all been implicated. 2, 3 Our previous studies have shown that patients with PCT frequently have concurrent acute GVHD (aGVHD) and that PCT responds to systemic steroid treatment. 1, 2 Considering that steroid therapy may impair GVL reactions and therefore theoretically increase the incidence of post transplant relapse, we investigated the outcomes of patients who developed PCT after myeloablative HCT for hematologic malignancies.
Materials and methods

Study design
A total of 324 consecutive children with ALL, AML or CML underwent allo-HCT at the University of Minnesota between 1993 and 2006. Of the 14 patients with PCT, 10 were previously reported by Woodard et al.;
2 however, the main end point of this study (leukemia relapse) was not addressed in that report. All protocols were approved by the institutional review board, and patients/guardians provided informed consent.
Preparative therapy and supportive care
All patients received myeloablative conditioning therapy and GVHD prophylaxis as previously described. 5, 6 Supportive care included HEPA filtered rooms, herpes simplex and Pneumocystis (carinii) jiroveci pneumonia prophylaxis, CMV surveillance, post transplant G-CSF and therapy for aGVHD and cGVHD as previously described. 5, 7, 8 Over the course of this retrospective analysis, there was no systematic approach to patients with pulmonary decompensation after transplant. In general, the majority of patients were analyzed by chest computed tomography and bronchoscopy. If pulmonary lesions were identified, patients were treated with broad-spectrum antimicrobials and antifungals. If pulmonary lesions were unresponsive to therapy or concerning for PCT, lung biopsy is subsequently considered if the lesions are surgically accessible. Treatment for histologically diagnosed PCT generally consisted of 1-2 mg/kg/day or prednisone (or equivalent methylprednisone dosing) until resolution of pulmonary symptoms (typically 1-2 weeks) followed by a rapid taper over 2-4 weeks. With this approach, some patients had a recurrence of symptoms either during or after the taper. Such patients were subsequently retreated with corticosteroids. In general, systemic corticosteroids were not use for pulmonary decompensation when pulmonary infiltrates and/or nodules were present.
Outcome end points and definitions
End points included aGVHD (grades II-IV and grades III-IV), cGVHD, OS, leukemia-free survival (LFS), relapse and treatment-related mortality (TRM). High-risk leukemia was defined as ALL in relapse, CR1, CR2 (relapse o36 months from diagnosis) or XCR3, AML in relapse or XCR2 or CML in accelerated phase or blast crisis. GVHD was graded according to published criteria with histopathological confirmation when possible. 8, 9 Patients with engraftment were considered evaluable for GVHD. LFS was defined as the time from transplant until disease recurrence, death or last patient contact, whichever came first. Survival was defined as the time from transplant until death or last contact. Relapse was defined as morphologic evidence of leukemia after HCT. TRM was defined as death in the first 3 years after HCT for any reason other than relapse.
Statistical analysis
Patient and transplant characteristics by donor type were analyzed using the w 2 -test for categorical data and the Wilcoxon rank-sum test for continuous data. The cumulative incidence of GVHD, TRM and relapse were calculated by treating deaths from other causes as competing risks. 10 LFS and OS were estimated by the Kaplan-Meier method.
11 Event times were measured from the date of transplantation to the event or the date of last contact. Time-event curves were completed by the log-rank test or Gray method. Multiple regression analysis was performed with Cox regression and the Gray and Fine competing hazards method.
12,13
Results
Patient demographics are presented in Table 1 . The median age at HCT was 12 years (range 4-17 years) in those with PCT and 9 years (range 0-18 years) in those without PCT. There were 178 patients with ALL, 128 with AML and 18 with CML. Stem cell sources included BM (n ¼ 206, 64%) and umbilical cord blood (n ¼ 118, 36%). Unrelated donor grafts (either BM or umbilical cord blood) were used in 64% of subjects. Fourteen subjects (4%, 95% CI 2-7%) developed biopsy-proven PCT at a median time of 3 months (range 1.3-11.3) after allo-HCT. Ten patients (71%) with PCT and 211 patients (68%) without PCT had high-risk leukemia (P ¼ 0.79). There were no significant differences between those with and without PCT with respect to age, gender, type of leukemia or CMV serostatus.
Similarly, there were no significant differences with respect to donor source (related vs unrelated), stem cell source (BM vs umbilical cord blood), degree of HLA disparity, conditioning regimen or GVHD prophylaxis.
The cumulative incidence of grades II-IV aGVHD for the entire cohort was 40%. Grades II-IV aGVHD was significantly higher in PCT patients (86%, n ¼ 12) when compared to those without PCT (38%, n ¼ 110) (Po0.01). The cumulative incidence of grades III-IV aGVHD for the entire cohort was 16% and was significantly greater in patients with PCT (43 vs 15%, P ¼ 0.01). Similarly, cGVHD was more common in PCT patients (36 vs 14%, P ¼ 0.02).
At 3 years, 86 patients had leukemia recurrence (27% (95% CI 22-32%)). In univariate analysis, the probability of relapse at 3 years was 0% in PCT patients and 28% (95% CI 23-34%) in patients without PCT (P ¼ 0.02) (Figure 1c) . The decreased risk of relapse persisted when we stratified for the presence of GVHD (0% in the PCT group, 18% (95% CI 10-25%) in non-PCT patients without grade II-IV aGVHD and 34% (95%CI 27-42%) in non-PCT patients with grade II-IV aGVHD (Po0.01)). In multivariate regression analysis, the only factors with a significant impact on relapse were the development of PCT (relative risk 0.0, Po0.01), grades II-IV aGVHD (relative risk 0.53, 95% CI 0.32-0.88, P ¼ 0.01) and cGVHD (relative risk 0.15, 95% CI 0.04-0.59, P ¼ 0.01) ( Table 2 ). The protective effect of PCT on relapse persisted in multivariate analysis when only the patients with aGVHD (grade II-IV) or cGVHD (n ¼ 137) were analyzed (relative risk 0.0, Po0.01). The probability of LFS for the entire cohort was 48% (95% CI 42-53%) at 3 years. PCT patients had a significantly higher probability of LFS when compared to those without PCT (79% (95% CI 47-93%) vs 47% (95% CI 41-52%), P ¼ 0.03) (Figure 1d) .
The cumulative incidence of TRM at 3 years for the entire cohort was 25%. TRM was not different in those with or without PCT (21 vs 25%, P ¼ 0.51). OS at 3 years was 49% (95% CI 43-54%) and was not different between those with and without PCT (71 vs 50%, P ¼ 0.12). Of the six deaths in the PCT group, five subjects had pulmonary complications at the time of death.
Discussion
To date, PCT has only rarely been reported as a complication following allo-HCT. A previous report from our institution showed that 15 of 33 transplant patients who developed pulmonary nodules and had them biopsied were given a histologic diagnosis of PCT. 14 The exact incidence of PCT post transplant is unknown, but is likely much lower than that report would indicate. Prior studies have shown that PCT is associated with aGVHD. [1] [2] [3] However, the influence of PCT on either cGVHD or relapse has not been addressed. Here we examined a cohort of patients transplanted for malignant hematological diseases who developed PCT. When compared to controls, PCT patients experienced more aGHVD (grade II-IV/III-IV) and cGVHD. Despite the increased probability of GVHD, a negative impact on either TRM or OS was not observed. Prior reports have shown that both aGVHD and cGVHD are associated with relapse protection. 15, 16 Here, using multivariate analysis, we show that PCT is independently associated with relapse protection. This protection is evident despite treatment of PCT with a short course of corticosteroids.
Although patients with PCT are at higher risk for developing cGVHD and pulmonary-associated toxicity, they have similar overall TRM and a lower risk of relapse. Further observations in patients with PCT are needed to confirm these findings, but it appears that the underlying etiology of these lesions may provide a protective effect with regard to leukemia relapse after allo-HCT.
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